EUcanAI European Unified Cancer diagnostics and treatment AI agent
- Coordinator
- Ruprecht-Karls-Universitaet Heidelberg, Germany
- Runs
- 1 September 2026 to 31 August 2030
- Status
- Running
- EU funding
- €3.9m
- Total cost
- —
- Partners
- 14 organisations in 5 countries
- Type
- European Innovation Council
- Grant agreement
- 101306931
What the project is doing
In the project's own words, from its summary on CORDIS.
The EUcanAI project pioneers a new paradigm for clinical management of central nervous system (CNS) cancers by creating a modular, agentic Generative AI ecosystem that unifies diagnosis and treatment into an integrated continuum of care. Current workflows in neuro-oncology are fragmented, slow, and highly dependent on individual expertise, leading to variable outcomes. EUcanAI transforms this landscape by developing interoperable AI agents that interact across three technological domains: (i) multimodal integration through an orchestration agent capable of synthesising clinical, imaging, histopathological and molecular data into transparent tumour board recommendations; (ii) medical data augmentation via generative models that produce synthetic MRI sequences, FFPE-quality histology from frozen sections, and rare diagnostic scenarios for model training and benchmarking; and (iii) knowledge representation and reasoning frameworks aligned with WHO CNS tumour classifications, ensuring transparent provenance, reproducibility, and explainable decision support.
The consortium unites 13 leading institutions across 3 EU Member States (Germany, Austria, Denmark), 1 Associated Partner (Korea), and 1 international collaborator (WHO-IARC), ensuring regional diversity, complementary expertise, and global external validation. This partnership enables access to the largest harmonised CNS tumour datasets in Europe (>10,000 cases) and world-class clinical infrastructures for multi-centre validation.
Through staged retrospective and prospective studies, EUcanAI will deliver clinically validated, human-in-the-loop AI systems supporting every step of CNS cancer care—from patient history extraction to intraoperative diagnostics and therapeutic planning. By embedding regulatory compliance with the EU AI Act, MDR and GDPR from inception, EUcanAI ensures trustworthy, sovereign and clinically adoptable AI.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ruprecht-Karls-Universitaet Heidelberg | Heidelberg | Germany | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Medizinische Universitat Innsbruck | Innsbruck | Austria | Participant |
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Participant |
| Johann Wolfgang Goethe-Universitaet Frankfurt Am Main | Frankfurt Am Main | Germany | Participant |
| Technische Hochschule Koln | Koln | Germany | Participant |
| Universitaet Greifswald | Greifswald | Germany | Participant |
| Universitaetsklinikum Essen | Essen | Germany | Participant |
| Universitatsklinikum Bonn | Bonn | Germany | Participant |
| Universitatsklinikum Erlangen | Erlangen | Germany | Participant |
| Kobenhavns Universitet | Kobenhavn | Denmark | Participant |
| Centre International De Recherche Sur Le Cancer | Lyon 7eme | France | Participant |
| Asan Medical Center | Seoul | South Korea | Associatedpartner |
| Yonsei University | Seoul | South Korea | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI